Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 1/20 | 0.50 |
| ▸ | RXRB | P28702 | 1/20 | 0.50 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.47 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.47 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.47 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.47 |
| ▸ | FFAR4 | Q5NUL3 | 3/20 | 0.47 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.47 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.47 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.47 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.47 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.47 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.47 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.47 |
| ▸ | FPR1 | P21462 | 1/20 | 0.47 |
| ▸ | FPR3 | P25089 | 1/20 | 0.47 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.47 |
| ▸ | HTR1D | P28221 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5989548 | 0.87 | RXRA (0.59) | RXRARXRBOPRM1MAPTOPRD1 | |
| SCHEMBL23358421 | 0.85 | PARP10 (0.50) | RXRARXRBOPRM1MAPTOPRD1 | |
| SCHEMBL5989500 | 0.85 | NPC1 (0.56) | RXRARXRBOPRM1MAPTOPRD1 | |
| SCHEMBL8782089 | 0.85 | RXRA (0.50) | RXRARXRBOPRM1MAPTOPRD1 | |
| SCHEMBL8782235 | 0.82 | FFAR1 (0.47) | RXRARXRBOPRM1MAPTOPRD1 | |
| SCHEMBL8185347 | 0.82 | KDM4E (0.53) | RXRARXRBOPRM1MAPTOPRD1 | |
| SCHEMBL7275027 | 0.76 | TSHR (0.53) | FFAR4MAOBNPC1RAB9AKMT2A | |
| SCHEMBL7275470 | 0.75 | TSHR (0.51) | MAPTFFAR4S1PR1MAOBNPC1 | |
| SCHEMBL18182225 | 0.74 | FFAR1 (0.49) | RXRARXRBMAPTFFAR4MAOB | |
| SCHEMBL8593937 | 0.74 | FFAR1 (0.40) | RXRARXRBOPRM1MAPTOPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10308652-B2 | Tricyclic heterocyclic compounds useful as inhibitors of TNF | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-06-04 | — | — | US | disclosed |
| US-20180111937-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS USEFUL AS INHIBITORS OF TNF | BRISTOL MYERS SQUIBB CO (US) | 2018-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180111937-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS USEFUL AS INHIBITORS OF TNF | TNF, TNFRSF1A, TNFRSF9 | RXRA 97/4885RXRB 115/4885OPRM1 2544/4885 |
| US-10308652-B2 | Tricyclic heterocyclic compounds useful as inhibitors of TNF | TNF, TNFRSF1A, TNFRSF9 | RXRA 97/4885RXRB 115/4885OPRM1 2544/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.